Novo Nordisk's Wegovy pill sales top Wall Street forecasts in third quarter
The oral obesity drug's strong numbers widen Novo's early lead over Eli Lilly in the pill segment of the weight loss market.
Read at Biopharmadive โFull coverage ยท 8 outlets
- Biopharmadive ยท lead
- BioPharma DiveNovo gets much-needed lift as Wegovy pill tops Wall Street forecasts
- Yahoo FinanceNovo Nordisk CEO: Wegovy pill 'exceeded our expectations'
- BigGo FinanceNovo Nordisk Lifts 2026 Guidance as Wegovy Pill Sales Top Forecasts
- ReutersNovo hikes outlook again as it speeds up Wegovy pill rollout
- FirstWord PharmaNovo's upbeat forecast can't overcome disappointments from oral Wegovy, CagriSema
- TipRanksNovo Reports Q3 Beat, Raises 2026 Sales Forecast on Obesity Demand; NVO Stock Jumps 5%
- YahooNovo gets much-needed lift as Wegovy pill tops Wall Street forecasts